HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) CME Activity Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ben-Haim, S. Articles by Ell, P. Search for Related Content PubMed PubMed Citation Articles by Ben-Haim, S. Articles by Ell, P.

¹⁸F-FDG PET and PET/CT in the Evaluation of Cancer Treatment Response^*

Institute of Nuclear Medicine University College London, London, United Kingdom

Correspondence: For correspondence or reprints contact: Simona Ben-Haim, Institute of Nuclear Medicine, University College London Hospital, NHS Trust, 235 Euston Rd. T5, London, NW1 2BU U.K. E-mail: Simona.ben-haim{at}uclh.nhs.uk

Multimodality imaging, as represented by its greatest exponent, PET/CT, has a firm place in the evaluation of a patient presenting with cancer. With ¹⁸F-FDG, PET/CT is rapidly becoming the key investigative tool for the staging and assessment of cancer recurrence. In the last 5 y, PET/CT has also gained widespread acceptance as a key tool used to demonstrate early response to intervention and therapy. In this setting, a major clinical need is being addressed with ¹⁸F-FDG PET/CT, because of its inherent ability to demonstrate (before other markers of response) if disease modification has occurred. This review presents available evidence to this effect.

Key Words: ¹⁸F-FDG • PET • PET/CT • tumor response • treatment monitoring • outcome

^* NOTE: FOR CE CREDIT, YOU CAN ACCESS THIS ACTIVITY THROUGH THE SNM WEB SITE (http://www.snm.org/ce_online) THROUGH JANUARY 2010.

The authors have indicated no relevant relationships that could be perceived as a real or apparent conflict of interest. No other potential conflict of interest relevant to this article was reported.

COPYRIGHT © 2009 by the Society of Nuclear Medicine, Inc.

Related articles in JNM:

This Month in JNM

JNM 2009 50: 11A-12A. [Full Text]  

This article has been cited by other articles:

				C. Yang, J. Sudderth, T. Dang, R. M. Bachoo, J. G. McDonald, and R. J. DeBerardinis Glioblastoma Cells Require Glutamate Dehydrogenase to Survive Impairments of Glucose Metabolism or Akt Signaling Cancer Res., October 15, 2009; 69(20): 7986 - 7993. [Abstract] [Full Text] [PDF]

				M. G. Vander Heiden, L. C. Cantley, and C. B. Thompson Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation Science, May 22, 2009; 324(5930): 1029 - 1033. [Abstract] [Full Text] [PDF]